<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26512078</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Identification of Positively Charged Residues in Enterovirus 71 Capsid Protein VP1 Essential for Production of Infectious Particles.</ArticleTitle><Pagination><StartPage>741</StartPage><EndPage>752</EndPage><MedlinePgn>741-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02482-15</ELocationID><Abstract><AbstractText Label="UNLABELLED">Enterovirus 71 (EV71), a positive-stranded RNA virus, is the major cause of hand, foot, and mouth disease (HFMD) in children, which can cause severe central nervous system disease and death. The capsids of EV71 consist of 60 copies of each of four viral structural proteins (VP1 to VP4), with VP1, VP2, and VP3 exposed on the surface and VP4 arranged internally. VP1 plays a central role in particle assembly and cell entry. To gain insight into the role of positively charged residues in VP1 function in these processes, a charged-to-alanine scanning analysis was performed using an infectious cDNA clone of EV71. Twenty-seven mutants containing single charged-to-alanine changes were tested. Sixteen of them were not viable, seven mutants were replication defective, and the remaining four mutants were replication competent. By selecting revertants, second-site mutations which could at least partially restore viral infectivity were identified within VP1 for four defective mutations and two lethal mutations. The resulting residue pairs represent a network of intra- and intermolecular interactions of the VP1 protein which could serve as a potential novel drug target. Interestingly, mutation K215A in the VP1 GH loop led to a significant increase in thermal stability, demonstrating that conditional thermostable mutants can be generated by altering the charge characteristics of VP1. Moreover, all mutants were sensitive to the EV71 entry inhibitor suramin, which binds to the virus particle via the negatively charged naphthalenetrisulfonic acid group, suggesting that single charged-to-alanine mutation is not sufficient for suramin resistance. Taken together, these data highlight the importance of positively charged residues in VP1 for production of infectious particles.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Infection with EV71 is more often associated with neurological complications in children and is responsible for the majority of fatalities. No licensed vaccines or antiviral therapies are currently available for the prevention or treatment of EV71 infection. Understanding the determinants of virion assembly and entry will facilitate vaccine development and drug discovery. Here, we identified 23 out of 27 positively charged residues in VP1 which impaired or blocked the production of infectious particles. The defect could be rescued by second-site mutations within the VP1 protein. Our findings highlight the importance of positively charged residues in VP1 during infectious particle production and reveal a potential strategy for blocking EV71 infections by inhibiting intra- or intermolecular interactions of the VP1 protein.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shilin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guiming</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China School of Life Sciences, Shanghai University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yizhuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China School of Life Sciences, Shanghai University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmeyer</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China raltmeyer@ips.ac.cn gangzou@ips.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Gang</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9607-7827</Identifier><AffiliationInfo><Affiliation>Unit of Anti-Infective Research, Key Laboratory of Molecular Virology &amp; Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China raltmeyer@ips.ac.cn gangzou@ips.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059386" MajorTopicYN="N">Reverse Genetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055672" MajorTopicYN="Y">Static Electricity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013489" MajorTopicYN="N">Suppression, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26512078</ArticleId><ArticleId IdType="pmc">PMC4702679</ArticleId><ArticleId IdType="doi">10.1128/JVI.02482-15</ArticleId><ArticleId IdType="pii">JVI.02482-15</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129:304&#x2013;309. doi:10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, Cowling BJ, Varma JK, Farrar JJ, Leung GM, Yu H. 2014. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 14:308&#x2013;318. doi:10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341:929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9:78&#x2013;85. doi:10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, How OM, Cardosa MJ, McMinn PC. 2007. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13:1733&#x2013;1741. doi:10.3201/eid1311.070632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1311.070632</ArticleId><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. 2010. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 7:94. doi:10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiff A. 2012. Cambodia unravels cause of mystery illness. Lancet 380:206. doi:10.1016/S0140-6736(12)61201-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61201-X</ArticleId><ArticleId IdType="pubmed">22826834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung YA, Hung CT, Liu YC, Shih SR. 2014. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther 14:1455&#x2013;1464. doi:10.1517/14712598.2014.935330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2014.935330</ArticleId><ArticleId IdType="pubmed">24989170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer E, Hellen CU, Cao X. 1993. Genetics of poliovirus. Annu Rev Genet 27:353&#x2013;436. doi:10.1146/annurev.ge.27.120193.002033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.ge.27.120193.002033</ArticleId><ArticleId IdType="pubmed">8122908</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello V. 2006. Picornaviridae: the viruses and their replication, p 796&#x2013;838. In Knipe D, Howley P (ed), Fields virology, 5th ed Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses. Curr Top Microbiol Immunol 343:43&#x2013;89. doi:10.1007/82_2010_37.20397067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/82_2010_37.20397067</ArticleId><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T, King A, Lea S, Newman J, Stuart D. 1997. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. J Virol 71:9743&#x2013;9752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ, Hogle JM. 1994. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci 3:1651&#x2013;1669. doi:10.1002/pro.5560031005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031005</ArticleId><ArticleId IdType="pmc">PMC2142606</ArticleId><ArticleId IdType="pubmed">7849583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794&#x2013;797. doi:10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. doi:10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Chuang H, Yang KD. 2009. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J 6:141. doi:10.1186/1743-422X-6-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. 2012. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol 12:162. doi:10.1186/1471-2180-12-162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-12-162</ArticleId><ArticleId IdType="pmc">PMC3478995</ArticleId><ArticleId IdType="pubmed">22853823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 85:11809&#x2013;11820. doi:10.1128/JVI.00297-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. doi:10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N, Cong H, Tian H, Zhang H, Zhang W, Song L, Tien P. 2014. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol 88:5816&#x2013;5833. doi:10.1128/JVI.03826-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03826-13</ArticleId><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. 2013. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 9:e1003240. doi:10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, van Belle S, Turin L, Zdobnov E, Kaiser L, Tapparel C. 2012. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 8:e1002826. doi:10.1371/journal.ppat.1002826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 2013. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9:e1003511. doi:10.1371/journal.ppat.1003511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SC, Li WC, Chen GW, Tsao KC, Huang CG, Huang YC, Chiu CH, Kuo CY, Tsai KN, Shih SR, Lin TY. 2012. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J Med Virol 84:931&#x2013;939. doi:10.1002/jmv.23287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23287</ArticleId><ArticleId IdType="pubmed">22499017</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zou Q, Chen L, Zhang H, Wang Y. 2011. Molecular analysis of virulent determinants of enterovirus 71. PLoS One 6:e26237. doi:10.1371/journal.pone.0026237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026237</ArticleId><ArticleId IdType="pmc">PMC3198388</ArticleId><ArticleId IdType="pubmed">22039449</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC, Peng KC, Chao YS. 2004. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother 48:3523&#x2013;3529. doi:10.1128/AAC.48.9.3523-3529.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89:2518&#x2013;2530. doi:10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X, Sheng L, Zhang Y, Guillon P, Arenzana-Seisdedos F, Buchy P, Li J, von Itzstein M, Li Q, Altmeyer R. 2014. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection&#x2014;suramin inhibits EV71 infection in vitro &amp; in vivo. Emerg Microbes Infect 3:e62. doi:10.1038/emi.2014.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.60</ArticleId><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Qing J, Sun Y, Rao Z. 2014. Suramin inhibits EV71 infection. Antiviral Res 103:1&#x2013;6. doi:10.1016/j.antiviral.2013.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.008</ArticleId><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. 2015. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother 59:2654&#x2013;2665. doi:10.1128/AAC.05108-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G, Zhang B, Lim PY, Yuan Z, Bernard KA, Shi PY. 2009. Exclusion of West Nile virus superinfection through RNA replication. J Virol 83:11765&#x2013;11776. doi:10.1128/JVI.01205-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01205-09</ArticleId><ArticleId IdType="pmc">PMC2772679</ArticleId><ArticleId IdType="pubmed">19726510</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, AbuBakar S. 2010. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 10:404&#x2013;412. doi:10.1016/j.meegid.2009.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2009.05.010</ArticleId><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, Ding J, Han JF, Zhang Y, Wu XY, He YL, Qin CF, Chen R. 2014. Human enterovirus 71 uncoating captured at atomic resolution. J Virol 88:3114&#x2013;3126. doi:10.1128/JVI.03029-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03029-13</ArticleId><ArticleId IdType="pmc">PMC3957924</ArticleId><ArticleId IdType="pubmed">24352461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateo R, Luna E, Rincon V, Mateu MG. 2008. Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J Virol 82:12232&#x2013;12240. doi:10.1128/JVI.01553-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01553-08</ArticleId><ArticleId IdType="pmc">PMC2593342</ArticleId><ArticleId IdType="pubmed">18829763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Cao RY, Chen R, Mo L, Han JF, Wang X, Xu X, Jiang T, Deng YQ, Lyu K, Zhu SY, Qin ED, Tang R, Qin CF. 2013. Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions. Proc Natl Acad Sci U S A 110:7619&#x2013;7624. doi:10.1073/pnas.1300233110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1300233110</ArticleId><ArticleId IdType="pmc">PMC3651461</ArticleId><ArticleId IdType="pubmed">23589862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287:6406&#x2013;6420. doi:10.1074/jbc.M111.301622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG. 1994. Viral cell recognition and entry. Protein Sci 3:1712&#x2013;1725. doi:10.1002/pro.5560031010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031010</ArticleId><ArticleId IdType="pmc">PMC2142612</ArticleId><ArticleId IdType="pubmed">7849588</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, He Y, Kuhn RJ. 2002. Picornavirus-receptor interactions. Trends Microbiol 10:324&#x2013;331. doi:10.1016/S0966-842X(02)02383-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-842X(02)02383-1</ArticleId><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>